Short-term clinical outcomes after HLA 1-locus mismatched uPBSCT are similar to that after HLA-matched uPBSCT and uBMT

Fuji, Shigeo; Miyamura, Koichi; Kanda, Yoshinobu; Fukuda, Takahiro; Kobayashi, Takeshi; Ozawa, Yukiyasu; Iwato, Koji; Uchida, Naoyuki; Eto, Tetsuya; Ashida, Takashi; Mori, Takehiko; Sawa, Masashi; Ichinohe, Tatsuo; Atsuta, Yoshiko; Kanda, Junya

doi:10.1007/s12185-019-02631-z

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of the patient subgroups were related to the graft source in the authors' study. It is especially notable that HLA status (matched versus mismatched) and conditioning regimen (myeloablative versus reduced intensity) did not interact with the graft source with respect to outcomes, which is in agreement with previous reports [52,53]. Thus, the authors' data support the use of unrelated PBSC grafts for adult AML patients irrespective of HLA status and conditioning regimen.…”

Section: Article In Presssupporting

confidence: 89%

Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients

Arai

Kondo

et al. 2022

Cytotherapy

Self Cite

View full text Add to dashboard Cite

Section: Article In Presssupporting

confidence: 89%

Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients

Arai

Kondo

et al. 2022

Cytotherapy

Self Cite

View full text Add to dashboard Cite

“…Fuji et al 24 showed that there were no statistically significant differences in the rates of grade III–IV aGVHD, NRM, and OS between 1 allele‐mismatched and 1 antigen‐mismatched HSCT groups. Furthermore, a recent population study from Japan reported that the outcomes of 1 locus‐mismatched HSCT were also comparable in unrelated PBSCT and unrelated BMT, including III–IV aGVHD, NRM, and OS 25 . Moreover, Kawamura et al 9 showed that low‐dose ATG conditioning reduced the rates of grade III–IV aGVHD, NRM, and overall mortality in the recipients of 1 locus‐mismatched HSCT.…”

Section: Discussionmentioning

confidence: 99%

Human leukocyte antigen disparities reduce relapse after hematopoietic stem cell transplantation in children with juvenile myelomonocytic leukemia: A single‐center retrospective study from China

Lin

Luo

Yan

et al. 2020

Pediatric Transplantation

View full text Add to dashboard Cite

Background HSCT is the only proven curative therapy for JMML. Matching donor and recipient HLA alleles is considered optimal to reduce the risk of GVHD after HSCT but is not always possible. Only a limited number of studies have compared the influence of HLA disparities on HSCT outcomes for patients with JMML. Methods We conducted a retrospective study among 47 children with JMML who received related or unrelated unmanipulated HSCT (March 2010‐October 2018). Among our participants, 27 (57.4%) donor‐recipient pairs had 0‐1 HLA disparities (Group 1: HLA‐matched or ≤1 allele/antigen mismatch donor) and 20 (42.6%) had ≥2 HLA disparities (Group 2: 2‐3 mismatched/haploidentical donors). Results The median follow‐up period was 26.0 months (range: 1‐105 months), and the 5‐year probabilities of DFS and RI for the whole cohort were 54.6 ± 7.7% and 34.8 ± 15.0%, respectively. Compared to Group 1, Group 2 patients had a significantly lower RI (5.3 ± 10.5% vs 55.5 ± 20.9%, P ˂ .001), though similar rates of grade II–IV acute GVHD (60.0 ± 22.4% vs 33.3 ± 18.2%, P = .08), grade III–IV acute GVHD (25.0 ± 19.5% vs 7.4 ± 10.1%, P = .08), chronic GVHD (30.0 ± 20.9% vs 34.9 ± 18.8%, P = .85), NRM (20.0 ± 18.0% vs 3.9 ± 7.7%, P = .07), and DFS (74.4 ± 9.9% vs 41.3 ± 10.0%, P = .08). Conclusions Disease relapse remains the major cause of treatment failure in JMML patients, especially in patients receiving HLA‐matched and limited HLA‐mismatched HSCT. Our findings suggest that donor‐recipient HLA disparities may improve the outcome of HSCT in children with JMML.

show abstract

Allogeneic Hematopoietic Cell Transplantation from Alternative Donors in Acute Myelogenous Leukemia: A Comparative Analysis

Yanada

Konuma

Yamasaki

et al. 2021

Transplantation and Cellular Therapy

View full text Add to dashboard Cite

Short-term clinical outcomes after HLA 1-locus mismatched uPBSCT are similar to that after HLA-matched uPBSCT and uBMT

Cited by 3 publications

References 24 publications

Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients

Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients

Human leukocyte antigen disparities reduce relapse after hematopoietic stem cell transplantation in children with juvenile myelomonocytic leukemia: A single‐center retrospective study from China

Allogeneic Hematopoietic Cell Transplantation from Alternative Donors in Acute Myelogenous Leukemia: A Comparative Analysis

Contact Info

Product

Resources

About